AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31163689
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene Citrate (CC) (50-150 mg for 3 months)
Trial: 19267775
Drug: Torasemide-PR (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide-PR (10 mg daily for 4 days)
Trial: 19267775
Drug: Torasemide-IR (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide-IR (10 mg daily for 4 days)
Trial: 7731378
Drug: Climen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climen (2 mg estradiol valerate and 1 mg cyproterone acetate)
Trial: 7731378
Drug: Prempak-C (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prempak-C (0.625 mg conjugated equine estrogens and 0.15 mg norgestrel)
Trial: 29429612
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg once daily (or 5 mg once daily for patients with creatinine clearance 40 to 60 mL/min)
Trial: 26192892
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg QD for 4 weeks in IMs
Trial: 26192892
Drug: Tamoxifen 40
RxNorm normalized name: tamoxifen 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 40 mg QD for 4 weeks in PMs
Trial: 26192892
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg QD for at least 4 weeks in EMs
Trial: 11396752
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus fosfomycin (2 g fosfomycin twice daily for 5 days)
Trial: 9430254
Drug: Thalidomide at
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at 100 mg/day for 24 weeks
Trial: 8487053
Drug: CPT-11 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 administered as a 100 mg/m2 weekly intravenous infusion or 150 mg/m2 every 2 weeks
Trial: 30802208
Drug: Topical NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical NAC (3 mL, 300 mg)
Trial: 30802208
Drug: Systemic NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic NAC (200 mg/kg once daily)
Trial: 30802208
Drug: Topical +
RxNorm normalized name: Topicale
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical + Systemic NAC (3 mL, 300 mg topical + 200 mg/kg systemic)
Trial: 26599232
Drug: Pre-admission treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-admission treatment types
Trial: 18155051
Drug: Anterior 3‐in‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior 3‐in‐1 femoral block with 30 mL of mepivacaine
Trial: 18155051
Drug: Posterior psoas
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior psoas compartment block with 30 mL of mepivacaine
Trial: 15577438
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel (40-120 mg/m2/cycle for the first 10 patients, 100 mg/m2/cycle for the subsequent 13 patients)
Trial: 15577438
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel
Trial: 10811493
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with carboplatin AUC 7 every 28 days for six courses (n = 81)
Trial: 10811493
Drug: Observation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation and chemotherapy at progression (Control group, n = 81)
Trial: 8697160
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg lisinopril
Trial: 6125345
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg chlormezanone
Trial: 6354600
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg chlormezanone
Trial: 6354600
Drug: Chlormezanone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlormezanone (both doses)
Trial: 29775246
Drug: Tramadol 400
RxNorm normalized name: tramadol hydrochloride 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 400 mg (therapeutic dose) on days 1-3, tramadol 100 mg and moxifloxacin-matched placebo on day 4, placebo on all 4 days
Trial: 29775246
Drug: Tramadol 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 600 mg (supratherapeutic dose) on days 1-3, tramadol 150 mg and moxifloxacin-matched placebo on day 4
Trial: 29775246
Drug: Placebo on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo on days 1-4 and moxifloxacin 400 mg on day 4
Trial: 26337213
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dexamethasone (4 mg) and hyaluronidase (750 IU)
Trial: 8092207
Drug: Ovesterin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovesterin 0.5 mg estriol vaginal pessaries
Trial: 30669587
Drug: Quercetin (Q)
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (Q) 1000 mg/day
Trial: 28318926
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg tranexamic acid followed by a continuous infusion of 1 mg/kg/h until the end of surgery
Trial: 23648395
Drug: DASH diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH diet intervention (8 group and 3 individual sessions over 3 months, followed by monthly phone consultations for another 3 months)
Trial: 10799374
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g AX-rich fiber
Trial: 10799374
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g AX-rich fiber
Trial: 4080297
Drug: recombinant interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recombinant interferon-alpha 2C monotherapy
Trial: 30953768
Drug: Endotoxin injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotoxin injection
Trial: 27005961
Drug: Fish-oil supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil supplementation (1800 mg of eicosapentaenoic acid and docosahexaenoic acid per day for 6 months)
Trial: 18940119
Drug: Conventional Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 12 weeks (Group-I, n=81)
Trial: 18940119
Drug: Conventional Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-II, n=81)
Trial: 18940119
Drug: Conventional Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Interferon 3 MIU, S/C, three times a week plus Ribavirin 800 to 1200 mg in divided doses daily for 24 weeks (Group-III, n=65)
Trial: 15857840
Drug: Fluorouracil-based first-line
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based first-line chemotherapy in patients with advanced mucinous CRC
Trial: 15857840
Drug: Fluorouracil-based first-line
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based first-line chemotherapy in patients with non-mucinous CRC (control group)
Trial: 12551866
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 to 60 mg/d
Trial: 12551866
Drug: Nifedipine and
RxNorm normalized name: nifedipine and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine and cerivastatin combination
Trial: 12551866
Drug: Cerivastatin 0.4
RxNorm normalized name: cerivastatin 0.4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin 0.4 mg/d
Trial: 9871860
Drug: Unoprostone isopropyl
RxNorm normalized name: Unoprostone Isopropyl
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unoprostone isopropyl 0.12% twice daily
Trial: 9871860
Drug: Unoprostone isopropyl
RxNorm normalized name: Unoprostone Isopropyl
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unoprostone isopropyl 0.12% three times daily
Trial: 7847298
Drug: Interferon-alpha (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (6 million units three times/wk for 6 months) plus ursodeoxycholic acid (10 mg/kg/day for 9 months)
Trial: 2140970
Drug: 1,500 mg
RxNorm normalized name: garlic 1,500 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg of acetyl-L-carnitine for 45 days
Trial: 16931685
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (PAS at nonacupoints on shoulders)
Trial: 7904489
Drug: rHuGM‐CSF at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuGM‐CSF at a dose of 125 micrograms/m2/d by continuous intravenous infusion (group 2)
Trial: 7904489
Drug: rHuGM‐CSF at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuGM‐CSF at a dose of 250 micrograms/m2/d by continuous intravenous infusion (group 3)
Trial: 8062862
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment with a pause of 2-3 months
Trial: 8062862
Drug: Continuous active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous active treatment without interruption
Trial: 380427
Drug: Intravenous physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous physostigmine (1.00 to 1.67 mg) administered at a rate of 0.5 mg/min every 4 min.
Trial: 380427
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (0.102 to 0.238 mg/kg body weight)
Trial: 380427
Drug: Intravenous physostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous physostigmine (1.00 to 1.67 mg)
Trial: 22483445
Drug: Torus mandibularis
RxNorm normalized name: Morus alba extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torus mandibularis bone chips combined with PRP gel
Trial: 19347685
Drug: EGb 761(R)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761(R) (240 mg per day)
Trial: 19347685
Drug: Donepezil (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (initially 5 mg, after 4 weeks 10 mg per day)
Trial: 19347685
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (EGb 761(R) and donepezil at the same doses)
Trial: 19347685
Drug: Donepezil mono-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil mono-therapy
Trial: 17497280
Drug: tirofiban+heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban+heparin
Trial: 7859897
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg twice a day
Trial: 6161
Drug: Timolol 30
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 30 to 60 mg daily
Trial: 6161
Drug: Propranolol 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 240 to 480 mg daily
Trial: 31392559
Drug: CoQ10 100
RxNorm normalized name: Walgreens CoQ10 100mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 100 mg/day for 2 months
Trial: 23847256
Drug: AZD1480 (10-70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1480 (10-70 mg QD and 20-45 mg b.i.d.)
Trial: 21030612
Drug: Monosodium glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium glutamate (MSG) 2 g
Trial: 19426177
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment before 21 weeks of gestation
Trial: 16960174
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg/d as zinc sulfate)
Trial: 9075561
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rectally of diclofenac (n = 31)
Trial: 3816879
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg intravenous infusion
Trial: 3816879
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral solution
Trial: 3816879
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tablet administration
Trial: 28381155
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy intervention (9-month outpatient intervention)
Trial: 21927052
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine (30 mg, 3 mL) plus triamcinolone (80 mg, 2 mL) and bupivacaine (0.25%, 3 mL)
Trial: 21927052
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection (80 mg triamcinolone, 2 mL) and 0.25% bupivacaine (3 mL) plus saline (3 mL)
Trial: 21927052
Drug: Epidural steroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural steroid injection with saline
Trial: 16612469
Drug: L-carnitine (CG)
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-carnitine (CG)
Trial: 8898645
Drug: Ribavirin plus
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin plus interferon alfa 2a (1200 mg oral ribavirin daily plus 3 million units of recombinant interferon alfa 2a thrice weekly for 24 weeks)
Trial: 8898645
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa 2a alone (3 million units thrice weekly for 24 weeks)
Trial: 1797521
Drug: Nicotine 0.5
RxNorm normalized name: nicotine 0.583 MG/HR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 0.5 mg
Trial: 1797521
Drug: Nicotine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 1.0 mg
Trial: 1797521
Drug: Nicotine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 2.0 mg
Trial: 30747773
Drug: BMS-936559 (10-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-936559 (10-900 mg)
Trial: 30747773
Drug: BMS-936559 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-936559 (900 mg)
Trial: 30747773
Drug: BMS-936559 (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-936559 (at two highest doses)
Trial: 19500154
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1200 mg once-daily with digoxin
Trial: 16337719
Drug: MVA-BN (IMVAMUNE)
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN (IMVAMUNE) vaccine, highest dose (10^8 TCID50)
Trial: 16337719
Drug: MVA-BN (IMVAMUNE)
RxNorm normalized name: MVA-BN
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA-BN (IMVAMUNE) vaccine
Trial: 15344392
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg once a day
Trial: 15344392
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg twice a day
Trial: 8369980
Drug: Inhaled cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled cetirizine
Trial: 3723261
Drug: 2:1 regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2:1 regimen (60 ml WHO‐ORS followed by 30 ml plain water)
Trial: 3723261
Drug: Diluted WHO‐ORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted WHO‐ORS (1.5 L water instead of 1 L)
Trial: 27181606
Drug: Indacaterol (110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol (110 μg) plus Glycopyrronium (50 μg) once daily
Trial: 27181606
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 μg) plus Fluticasone (500 μg) twice daily
Trial: 24084500
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4)
Trial: 24084500
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg aflibercept every 4 weeks (2q4)
Trial: 24084500
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg aflibercept every 4 weeks (0.5q4)
Trial: 24084500
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg aflibercept every 8 weeks (2q8)
Trial: 20738227
Drug: Dalcetrapib 900
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 900 mg with atorvastatin (concurrent dosing study)
Trial: 20738227
Drug: Dalcetrapib 600
RxNorm normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalcetrapib 600 mg with atorvastatin (interval dosing study)
Trial: 15689804
Drug: Oral steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroids (for 1 week)
Trial: 15689804
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral steroids
Trial: 1395875
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus preoperative chemotherapy (5-FU 1g/m2/d x 5 and cisplatin 20 mg/m2/d x 5)
Trial: 29653037
Drug: Manual Titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Titration (MT) technique
Trial: 23135529
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus naltrexone (0.7 mg/kg)
Trial: 23135529
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus naltrexone (0.7 mg/kg)
Trial: 18474932
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (3 doses, twice daily for 2 weeks)
Trial: 16040376
Drug: Pergolide (0.05-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pergolide (0.05-0.2 mg per day)
Trial: 16040376
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one to four tablets per day)
Trial: 12444336
Drug: Body-weight-independent (BWI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body-weight-independent (BWI) dosing of cyclosporine A (CsA) 100-300 mg for 12 weeks
Trial: 12444336
Drug: Body-weight-dependent (BWD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body-weight-dependent (BWD) dosing of cyclosporine A (CsA) 1.25-5.0 mg/kg for 12 weeks
Trial: 12444336
Drug: Intermittent CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent CsA treatment (after period I)
Trial: 12444336
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (after period I)
Trial: 6207983
Drug: Propranolol (40-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-320 mg/day)
Trial: 30710418
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene procedures performed/controlled by nursing home staff (n = 25)
Trial: 28636435
Drug: Contrast training
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast training programme (isometric + plyometric), twice a week for 10 weeks
Trial: 27213949
Drug: Bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300 mg/day) + Naltrexone (50 mg/day)
Trial: 27213949
Drug: Bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300 mg/day) + Placebo
Trial: 24489770
Drug: Antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole - ATM)
Trial: 24489770
Drug: Antibiotic combination
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic combination therapy (ATM)